- Mirogabalin
-
- $0.00 / 5kg
-
2025-01-22
- CAS:1138245-13-2
- Min. Order: 1kg
- Purity: 98
- Supply Ability: 1000
- Mirogabalin
-
- $35.00 / 1mg
-
2024-11-19
- CAS:1138245-13-2
- Min. Order:
- Purity: 99.89%
- Supply Ability: 10g
- Mirogabalin
-
- $0.00 / 1kg
-
2024-10-25
- CAS:1138245-13-2
- Min. Order: 1kg
- Purity: 99%
- Supply Ability: 100tons
|
| | Mirogabalin Basic information |
| Product Name: | Mirogabalin | | Synonyms: | Mirogabalin;[(1R,5S,6S)-6-(Aminomethyl)-3-ethylbicyclo[3.2.0]hept-3-en-6-yl]acetic acid;A200-0700;DS5565;A200-0700;2-[(1R,5S,6S)-6-(aminomethyl)-3-ethyl-6-bicyclo[3.2.0]hept-3-enyl]acetic acid;MIROGABALIN; DS-5565;DS 5565;DS-5565;DS5565;Bicyclo[3.2.0]hept-3-ene-6-acetic acid, 6-(aminomethyl)-3-ethyl-, (1R,5S,6S)- | | CAS: | 1138245-13-2 | | MF: | C12H19NO2 | | MW: | 209.28 | | EINECS: | | | Product Categories: | API;1138245-13-2 | | Mol File: | 1138245-13-2.mol |  |
| | Mirogabalin Chemical Properties |
| Boiling point | 357.5±15.0 °C(Predicted) | | density | 1.104±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMF:0.5(Max Conc. mg/mL);2.39(Max Conc. mM)
Ethanol:1.25(Max Conc. mg/mL);5.97(Max Conc. mM)
PBS (pH 7.2):0.5(Max Conc. mg/mL);2.39(Max Conc. mM)
Water:5.36(Max Conc. mg/mL);25.61(Max Conc. mM) | | form | A crystalline solid | | pka | 4.65±0.10(Predicted) | | color | Light yellow to light brown | | InChI | InChI=1S/C12H19NO2/c1-2-8-3-9-5-12(7-13,6-11(14)15)10(9)4-8/h4,9-10H,2-3,5-7,13H2,1H3,(H,14,15)/t9-,10-,12-/m1/s1 | | InChIKey | FTBQORVNHOIASH-CKYFFXLPSA-N | | SMILES | [C@]12([H])[C@]([H])([C@@](CN)(CC(O)=O)C1)C=C(CC)C2 |
| | Mirogabalin Usage And Synthesis |
| Description | Mirogabalin is a calcium channel blocker with analgesic effects. It binds to the α2δ-1 and α2δ-2 subunits of voltage-dependent Ca2+ channels. Mirogabalin has potent and sustained analgesic effects (ED50 = 2.5 mg/kg) in rats with diabetes induced by streptozotocin (STZ; ). Mirogabalin does not inhibit activities associated with CNS adverse effects of analgesics, such as rotarod performance (ID50 = 9.4 mg/kg) or locomotor activity (ID50 = 43.9 mg/kg), at its effective dose. Formulations containing mirogabalin are in clinical trials for diabetic peripheral neuropathic pain. | | Uses | Mirogabalin is a two alpha2delta ligand which is investigated for the treatment of peripheral neuropathic pain, postherpetic neuralgia and fibromyalgia, showing promising results in patients with diabetic peripheral neuropathy. | | Brand name | Mirogabalin (brand name Tarlige; developmental code name DS-5565) is a gabapentinoid medication developed by Daiichi Sankyo. | | Side effects | The most typical clinical adverse reactions of mirogabalin were dizziness (7.6%) and somnolence (5.1%). However, the occurrence rate was lower than with pregabalin, whose adverse effects were reported to include somnolence, balance disorder, fatigue, and peripheral edema, with an occurrence rate of 8.0%, 4.0%, 4.0%, and 4.0%, respectively[1]. | | Mode of action | Mirogabalin is an analog of the neurotransmitter, gamma-aminobutyric acid (GABA). It is a potent and specific ligand of the α2δ subunit of voltage-dependent Ca2+channels, which reduces calcium (Ca2+) influx and neurotransmission in dorsal root ganglia (DRGs), inhibiting neurotransmitter release in presynaptic neuron endings. | | References |
[1] Hui Tang. “The Clinical Application and Progress of Mirogabalin on Neuropathic Pain as a Novel Selective Gabapentinoids.” Mediators of Inflammation 2023 (2023): 4893436.
|
| | Mirogabalin Preparation Products And Raw materials |
|